ORPHENADRINE HYDROCHLORIDE - search results

rxchange co. - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9) - orphenadrine citrate 100 mg - orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug. orphenadrine has been chronically abused for its euphoric effects. the mood elevating effects may occur at therapeutic doses of orphenadrine.

United States - English - NLM (National Library of Medicine)

bupropion hydrochloride- bupropion hydrochloride tablet, extended release

ncs healthcare of ky, inc dba vangard labs - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 100 mg - bupropion hydrochloride extended-release tablets (sr) are indicated for the treatment of major depressive disorder. the efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of depressed inpatients and in one 6-week controlled trial of depressed outpatients whose diagnoses corresponded most closely to the major depression category of the apa diagnostic and statistical manual (dsm) (see clinical pharmacology). a major depressive episode (dsm-iv) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a

United States - English - NLM (National Library of Medicine)

orphenadrine citrate tablet, extended release

preferred pharmaceuticals, inc - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9) - orphenadrine citrate 100 mg - orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug. orphenadrine has been chronically abused for its euphoric effects. the mood elevating effects may occur at therapeutic doses of orphenadrine.